MicroPort CardioFlow Updates Board Composition and Committee Assignments

Bulletin Express
Jun 04

MicroPort CardioFlow Medtech Corporation released an updated schedule of its board members and their roles as of 4 June 2026, detailing both director positions and committee responsibilities.

The Board now consists of nine directors: • Non-executive Directors: Mr. Chen Guoming (Chairman) and Dr. Brian Chang (Co-Chairman) • Executive Directors: Mr. Zhang Ruinian (Chief Executive Officer) and Mr. Philippe Wanstok (President) • Non-executive Director: Mr. Deng Aoyi • Independent Non-executive Directors: Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang

Committee structure and leadership were also confirmed:

1. Audit Committee – Chair: Mr. Jonathan H. Chou – Members: Dr. Brian Chang, Ms. Sun Zhixiang, Dr. Hu Bingshan

2. Remuneration Committee – Chair: Ms. Sun Zhixiang – Members: Mr. Chen Guoming, Mr. Zhang Ruinian

3. Nomination Committee – Chair: Dr. Hu Bingshan – Members: Dr. Brian Chang, Mr. Philippe Wanstok, Ms. Sun Zhixiang

4. Strategy Committee – Chair: Mr. Chen Guoming – Members: Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok

5. Commercialization Committee – Chair: Dr. Brian Chang – Members: Mr. Chen Guoming, Mr. Deng Aoyi, Mr. Jonathan H. Chou, Dr. Hu Bingshan, Mr. Mao Junxiang

The announcement consolidates governance responsibilities across five specialized committees, underscoring the company’s adherence to a structured oversight framework as it advances its cardiovascular medical technology portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10